Swiss

Swiss Rockets AG is a Basel-based biotech incubator and accelerator that focuses on identifying and developing high-potential oncology and infectious disease startups. The company operates an integrated ecosystem that provides scientific expertise, operational infrastructure, and funding to its portfolio companies, which include RocketVax, Torpedo, and Lighthouse. Its pipeline features a diverse range of assets, including next-generation COVID-19 vaccines, radioligand therapies for solid tumors, and novel small molecules for cancer treatment. In early 2026, Swiss Rockets significantly expanded its capabilities by entering into a definitive agreement to acquire the genomic sequencing innovator Complete Genomics. The group aims to bridge the gap between academic research and commercial success through a rigorous screening process and a global distribution network.